Therapeutic Antibody Development

 

 

 

 

  Ultimate Humanization® Antibody

Fully Human Antibody

Humanized Antibody

Chimeric Antibody

New Technology 100% Fee-for-services
|

New Technology 100% Fee-for-services :

learn more... >>

 

IHC Antibody Development

 

 

 

 

  •  Exclusive Immunogen Design (IHC Peptide ProfilerTM)
  • Optimized for paraffin-embedded sections 
  • High throughput screening on IHC slides
BIOTEM solutions to enhance your success rate on paraffin-embedded sections
|

BIOTEM solutions to enhance your success rate on paraffin-embedded sections :

learn more... >>
A recombinant antibody plaftorm for high affinity (scFv and Ig formats)
|

A recombinant antibody plaftorm for high affinity (scFv and Ig formats) :

learn more... >>
BIOTEM provides high added value services for the development of hybridomas
|

BIOTEM provides high added value services for the development of hybridomas :

learn more... >>

 

 

  Custom Immunoassay

  Development

   ELISA & Lateral Flow

High quality & Custom ELISA & Lateral Flow
|

High quality & Custom ELISA & Lateral Flow :

learn more... >>
Development and production of monoclonal antibodies

BIOTEM is a Contract Research Organisation providing custom and high added value services in the field of immunotechnology.

 

Our company has major assets which enable us to successfully accomplish our missions:

Media
& Agenda
BIOFIT 2019
Dec.
10
BIOTEM will be present at the BIOFIT business convention on the 10-11th December in Marseille (France).
FESTIVAL OF BIOLOGICS
Oct.
15
BIOTEM will attend the Festival of Biologics which will be held on the 15th-17th October 2019 (Basel, Switzerland)
BIOPRODUCTION OF IMMUNOTHERAPIES
Sep.
24
BIOTEM will attend the 4th edition of Bioproduction of Immunotherapies which will be held on September 24th at Romainville...
Antibody Industrial Symposium 2019
Jun.
24
The 7th Antibody Industrial Symposium will be held on the 24-25th of June 2019 in Tours (France).
Labtoo
May.
29
BIOTEM is now listed on the European Labtoo platform for its sequencing and recombinant antibody production services